

Ref: FOI/GS/ID 6778

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

23 June 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to the treatment of lung cancer.

You asked:

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- a. Afatinib*
- b. Alectinib*
- c. Atezolizumab monotherapy*
- d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel*
- e. Bevacizumab*
- f. Brigatinib*
- g. Ceritinib*
- h. Crizotinib*
- i. Dacomitinib*
- j. Dabrafenib with Trametinib*
- k. Docetaxel monotherapy*
- l. Durvalumab*
- m. Erlotinib*
- n. Gefitinib*
- o. Gemcitabine*
- p. Nintedanib with Docetaxel*
- q. Nivolumab*
- r. Osimertinib*
- s. Paclitaxel*
- t. Pembrolizumab monotherapy*
- u. Pembrolizumab chemo in combination*
- v. Pemetrexed with Carboplatin*

- w. *Pemetrexed with Cisplatin*
- x. *Vinorelbine and cisplatin/carboplatin*
- y. *Any other active systemic anti-cancer therapy (SACT)*
- z. *Palliative care only*

Q2. *Could you please provide the total number of patients treated with any systemic anti-cancer therapy (SACT) in the last three months for:*

- a. *Total non-small cell lung cancer (NSCLC)*
- b. *Squamous non-small cell lung cancer (Sq NSCLC)*
- c. *Non-squamous non-small cell lung cancer (Non-Sq NSCLC)*

Q3. *Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?*

Trust response for the data period: 01/03/21 - 31/05/21:

Q1.

- a. 3
- b. 4
- c. 2
- d. 1
- e. 0
- f. 1
- g. 0
- h. 2
- i. 0
- j. 0
- k. 1
- l. 0
- m. 0
- n. 0
- o. 2
- p. 1
- q. 0
- r. 18
- s. 0
- t. 14
- u. 22
- v. 2
- w. 0
- x. 13
- y. 6
- z. 3

Q2.

- a. 12
- b. 2
- c. 10

Q3. The Trust is registered with 3 clinical trials: Skyscraper, Matrix and Flora 2, although there are currently no patients currently taking place in these trials.